Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Taiho Oncology, Inc.
NRG Oncology
Eli Lilly and Company
Hoffmann-La Roche
National Cancer Institute (NCI)
Guangzhou JOYO Pharma Co., Ltd
Merck Sharp & Dohme LLC
University Hospital, Limoges
Avistone Biotechnology Co., Ltd.
Checkpoint Therapeutics, Inc.
Novartis
Novartis
Sanofi
Hunan Province Tumor Hospital
Intergroupe Francophone de Cancerologie Thoracique
Innovent Biologics (Suzhou) Co. Ltd.
Eli Lilly and Company
University of Turin, Italy
Jiangsu HengRui Medicine Co., Ltd.
Incyte Corporation
Shanghai University of Traditional Chinese Medicine
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Martha-Maria Krankenhaus Halle-Dölau gGmbH
Tang-Du Hospital
National Cancer Institute (NCI)
Point Therapeutics